Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | ATG-based immunosuppressive therapy in elderly patients with aplastic anemia

Jayastu Senapati, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of a study evaluating the outcomes of elderly patients with aplastic anemia treated with anti-thymocyte globulin (ATG)-based immunosuppressive therapy. There were no significant differences in response rates (RR) and relapse-free survival (RFS) between older and younger patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.